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SEPSIS syndrome (SS) is associated with depressed PAF
acetylhydrolase,  the  enzyme  responsible  for  the
degradation of platelet activating factor. PAF acetylhy-
drolase is in a large part produced by macrophages,
whose inadequate activation with haemophagocyto-
sis is frequent in patients with SS.
The aim of this study was to test the hypothesis that
PAF acetylhydrolase levels could be affected in these
critically  ill  patients,  because  of  the  large  amounts
produced by activated macrophages in vitro and in
vivo in animal models.
The  levels  of  serum  PAF  acetylhydrolase  were
assessed  in  90  SS  patients,  who  were  divided  into
three  groups:  patients  with  (n =  34)  or  without
haemophagocytosis  (n =  31),  and  patients  without
thrombocytopenia  (n =  25)  who  were  used  as  a
control  group.  The  number  of  organ  dysfunctions
was matched between patients with haemophagocy-
tosis  and  controls.  Normal  reference  values  were
obtained in 59 randomly selected blood donors.
Circulating  levels  of  PAF  acetylhydrolase  were
significantly (p = 0.0001) decreased in patients with
SS (57 ± 3 nnol/ml/min, n = 90) when compared with
healthy subjects (69 ± 3 nmol/ml/min,  n = 59).  PAF
acetylhydrolase levels were greater in the presence of
a  haemophagocytosis  but  without  statistical  signifi-
cance (64.2 ± 6.5 vs 50.1 ± 2.8: p = 0.25).
Despite the fact that macrophagic activation stim-
ulates the in vitro release of PAF acetylhydrolase, no
difference was found between patients with or with-
out haemophagocytosis. The mechanism and the role
of  the PAF acetylhydrolase reduction in SS  patients
remain to be determined.
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Introduction
The sepsis syndrome (SS) is a complex inflammatory
response to various acute insults.1 Platelet-activating
factor (PAF), one of the main mediators involved in
the inflammatory response, is produced through the
metabolic  pathway  of  the  phospholipase A2  from
phospholipids of the cell membrane.2 PAF plays a key
role  in  the  initiation  and  development  of  various
critical diseases which are associated with increased
levels of phospholipase A2, including  septic shock,
adult  respiratory  distress  syndrome  and  multiple
organ failure (MOF).3 Blood concentrations of PAF are
regulated by a circulating enzyme, the PAF acetylhy-
drolase, which converts PAF into inactive lyso-PAF.4
Depressed PAF acetylhydrolase has been reported in
association with severe sepsis5 and  MOF.3 This dis-
regulation of PAF/PAF acetylhydrolase may result in an
amplified  inflammatory  response  secondary  to  the
increased half-life of circulating PAF. Monocytes and
macrophages physiologically participate in the regula-
tion  of  the  balance  of  PAF/PAF  acetylhydrolase.
Stimulated monocytes release a large fraction of their
newly synthesised PAF,6 whereas macrophages are a
major  source  of  PAF  acetylhydrolase,  this  process
being a mechanism for the resolution of the inflamma-
tory  response.7 Recently  a  study  has  demonstrated
that the PAF acetylhydrolase in human plasma origi-
nates from haematopoietic lineage cells.8
We have reported the frequent association between
severe SS with thrombocytopenia and haemophago-
cytosis.9 As  a  strong  macrophagic  differentiation
occurs in these patients,9 we hypothesized that PAF
acetylhydrolase levels could be affected in these SS
patients, because of the large amounts produced by
activated macrophages in vitro and in vivo in animal
models.10 We then conducted the present study  to
compare  the  levels  of  serum  PAF  acetylhydrolase
between  SS  patients with  or without  haemophago-
cytosis.
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Patients
All aspects of the study protocol were approved by
the committee on human investigations of our institu-
tion.  During  a  12-month  period,  all  consecutive
patients who fulfilled the following inclusion criteria
were studied: the presence of (1) an SS according to
Bone’s criteria,1 and (2) a thrombocytopenia (platelet
count  <  100000/mm3)  of  undetermined  origin.
Patients were excluded from the study when at least
one of the following criteria were present: hemato-
logical  disease,  previous  anticancer  chemotherapy,
major bleeding and/or prior transfusion of any blood
component,  disseminated  intravascular  coagulation
defined as the presence of a prothrombin time of less
than 50% of the control value together with either a
positive ethanol test or D-dimers test, and previous
administration of heparin. In each patient, the sever-
ity of the acute illness at the time of admission to the
intensive  care  unit  (ICU)  was  assessed  using  the
APACHE II score.11 The potential causes of the sepsis
syndrome as well as the number and nature of acute
organ system dysfunction were evaluated at the time
of enrolment.12 Patients were considered as infected
if  an  ongoing  infection  was  documented  at  enrol-
ment.  Bacteraemia  was  defined  by  at  least  two
positive blood cultures with the same pathogen. Focal
infections were diagnosed on the basis of both clinical
and microbiological findings. In each patient, a bone
marrow aspirate was performed at the day of enrol-
ment  to  study  the  cause  of  thrombocytopenia.  It
allowed  us  to  divide  patients  into  two  subsets,
according to the presence or absence of cytological
findings  associated  with  a  macrophagic  activation.
Haemophagocytosis  was  assessed  by  cytological
examination of May Gr¨ unwald Giemsa stained bone
marrow smears, using a previously described proto-
col.9 Haemophagocytosis was  diagnosed  when  the
percentage  of  macrophages  exceeded  2%  of  bone
marrow  nucleated  cells,  in  conjunction  with  the
presence of more than one haemophagocytic cell per
field at ´ 200 magnification.
During the same period, consecutive patients with
SS  but  no  thrombocytopenia  were  also  studied.
Although  the  bone  marrow  was  not  studied  for
ethical reasons in this group, the absence of thrombo-
cytopenia was considered as potentially predictive of
the absence of haemophagocytosis. Patients in  this
group  were matched in  terms  of  number  of  organ
dysfunctions,  according to  the  ODIN  score,12 with
those suffering from haemophagocytosis.
PAF acetylhydrolase measurement
Serum PAF acetylhydrolase levels were measured on
the day of enrolment by assessing the degradation of
[3H] acetyl-PAF.13 Briefly, 1 ´ 105 dpm of [3H] acetyl-
PAF, 10Ci/mmol (NEN, Les Ulis, France), 0.1 mM PAF
(Tebu,  France),  HEPES  buffer  (pH  7.8)  in  a  final
volume of 450ml, and 50ml of serum (1/50 dilution in
HEPES buffer) were incubated for 15min at 37°C. The
reaction  was  stopped  with  100ml  BSA  (10%)  and
500ml trichloracetic acid (20%). Samples were cen-
trifuged (1500 ´ g, 15min), supernatants were mixed
with 2.5ml of scintillation fluid (Opti-fluor, Packard,
France) and counted in a liquid scintillation counter
(Packard). Results  were  expressed as nanomoles of
PAF degraded perml of serum permin, as means of
duplicate  determinations.  Normal  reference  values
were established by measuring serum concentrations
of  PAF  acetylhydrolase  in  59  randomly  selected
healthy subjects.
Statistical analysis
Data  were  expressed  as  mean  ±  SEM.  Continuous
variables  were  compared  between  groups  using
either the Mann-Whitney U-test or the Kruskall Wallis
one-way  analysis  of  variance.  Qualitative  variables
were compared using the chi-square test, with correc-
tion for continuity when appropriate. A p value of <
0.05 was considered statistically significant.
Results
Ninety patients (mean age: 58 ± 2 years, APACHE II: 23
±  1)  were  enrolled  into  the  study.  Reasons  for
admission to the intensive care unit included multi-
system trauma (n = 15), complicated postoperative
course (n = 23), and severe medical illnesses (n = 52).
Seventy-four patients (82%) sustained a multiple organ
dysfunction and 31 (34%) died during their stay in the
ICU. Sixty-five patients were diagnosed with thrombo-
cytopenia. Megakaryocytic lineage was always normal.
Macrophagic activation was identified on bone mar-
row smears in 34 cases (52%). When compared with
patients without macrophagic activation, the presence
of a haemophagocytosis was associated with a higher
number of organ dysfunctions and greater infection
rate (Table 1). Patients without thrombocytopenia (n =
25) had a similar number of organ dysfunctions and
mortality rate, compared with those with haemopha-
gocytosis (Table 1).
When compared with healthy subjects, serum PAF
acetylhydrolase  was  significantly  decreased  in
patients with SS (57 ± 3nmol/ml/min vs 69 ± 3nmol/
ml/min,  p =  0.0001)  (Fig.  1).  Patients  sustaining
multisystem  trauma  had  significantly  (p <  0.01)
reduced  serum  PAF  acetylhydrolase  concentrations
(47 ± 3nmol/ml/min) when compared with patients
with SS of medical (58 ± 4nmol/ml/min) or surgical
origin (59 ± 6nmol/ml/min) (Fig. 1). In thrombocy-
topenic patients with haemophagocytosis, mean PAF
acetylhydrolase levels were greater than those meas-
ured  in  patients  without  macrophagic  activation
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significance (64 ± 6nmol/ml/min vs 50 ± 3nmol/ml/
min,  p =  0.25). When compared with  healthy sub-
jects, patients  with  haemophagocytosis had similar
serum  PAF  acetylhydrolase  concentrations  (64  ±
6nmol/ml/min  vs  69  ±  3nmol/ml/min,  p >  0.05)
whereas patients without macrophagic activation had
significantly lower levels (50 ± 3 vs 69 ± 3, p = 0.001).
SS patients with or without thrombocytopenia do not
have different serum PAF acetylhydrolase levels (Fig.
1).  Circulating  PAF  acetylhydrolase levels  were  not
significantly increased in the presence of a bacterial
infection  (51  ±  4nmol/ml/min  vs  59  ±  4nmol/ml/
min,  p =  0.47)  and  were  not  predictive  of  fatal
outcome  (58  ±  7nmol/ml/min  vs  55  ±  4nmol/ml/
min,  p =  0.68).  Both  number  and  nature  of  organ
dysfunctions  were  not  correlated  with  serum  PAF
acetylhydrolase  levels  (data  not  shown),  with  the
exception  of  neurological  dysfunction  which  was
associated with lower levels (47 ± 3nmol/ml/min vs
60 ± 4nmol/ml/min, p = 0.04).
Discussion
In the present study, decreased levels of PAF acetylhy-
drolase were found in patients with SS when compared
with healthy subjects.  This finding is in agreement with
previously reported results in patients suffering from
sepsis5 and  MOF.3 Reduction  of  the  PAF  acetylhy-
drolase  in  these  settings  is  thought  to  increase
substantially the half-life  of  PAF,  which in turn may
amplify the inflammatory cascade in response to an
acute insult,  leading to MOF.14 Although lower PAF
acetylhydrolase levels have been reported in patients
who die from sepsis when compared with survivors,5
they  were  not  predictive  of  the  outcome  in  our
patients. In addition, we did not confirm the correla-
tion  between  PAF  acetylhydrolase  levels  and  the
number of organ dysfunctions previously reported.3
Such  a  discrepancy  may  be  explained  by  different
study  designs.  In  the  present  study,  PAF  acetylhy-
drolase levels were measured when MOF was already
initiated, whereas Partrick et al.3 compared the PAF
acetylhydrolase  determined  at  admission  with  sub-
sequent occurrence of organ dysfunctions during the
ICU  stay.  Patients  with  SS  secondary  to  severe
multisystem  trauma  had  lower  PAF  acetylhydrolase
levels than those with SS of medical or surgical origin.
Direct tissue injuries observed in patients sustaining
severe trauma may lead to extensive cellular damage
and  subsequent  elevated phospholipase A2  activity.
Increased release of PAF by injured tissue associated
with  reduced  levels  of  serum  PAF  acetylhydrolase
might amplify organ dysfunctions in this setting when
compared with SS of other origin.
PAF acetylhydrolase and sepsis syndrome
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Table 1. Characteristics of the different subsets of patients with sepsis syndrome
Without
thrombocytopenia
(n = 25)
Thrombocytopenia
without
haemophagocytosis
(n = 31)
Thrombocytopenia
with
haemophagocytosis
(n = 34)
Age (years) 59 ± 3 56 ± 3 60 ± 2
Males (n) 19 (76) 19 (61) 25 (73)
APACHE II score 23 ± 1.4 22 ± 1.2 23 ± 1.6
Organ dysfunctions 2.8 ± 0.1 2.0 ± 0.2 2.8 ± 0.2*
Type of organ dysfunction
Cardiovascular 17 (68) 11 (35) 25 (73)*
Respiratory 25 (100) 29 (93) 32 (94)
Hepatic 3 (12) 1 (3) 12 (35)*
Renal 12 (48) 11 (35) 16 (47)
Neurologic 14 (56) 8 (25) 6 (17)
Haematologic 0 0 5 (14)*
Infections 16 (64) 11 (35) 21 (61)*
Death 8 (32) 8 (25) 15 (44)
* p < 0.01 when compared with patients without haemophagocytosis. Numbers between parentheses are percentages.
FIG. 1. Serum PAF acetylhydrolase concentrations in patients
with a sepsis syndrome (SS). Data are shown for subsets of
patients  admitted  to  the  intensive  care  unit  for  medical
(medSS) or surgical illness (surgSS), for multisystem trauma
(trauSS) and for subgroups of patients with thrombocytope-
nia  plus  haemophagocytosis (H+T+SS),  thrombocytopenia
without  haemophagocytosis (H–T+SS)  or  patients  without
thrombocytopenia (H–T–SS). NS = non-significant.As previously reported,9 haemophagocytosis occur-
red  frequently  in  thrombopenic  patients  with  SS
(52%). When  compared  with  patients  without  evi-
dence of macrophagic activation, patients with hae-
mophagocytosis exhibited a greater number of organ
dysfunctions  and  a  higher  frequency  of  bacterial
infections.  Despite the  great  level  of maturation  of
monocytes  to  macrophages  in  SS  patients  with
haemophagocytosis, their serum PAF acetylhydrolase
levels were only weakly elevated as compared with
patients  without  haemophagocytosis  or  without
thrombocytopenia. Moreover they were only similar
to  those of  healthy  subjects  when  a  much  greater
value was expected. In SS patients with haemophago-
cytosis  PAF  acetylhydrolase  production  might  be
insufficient  to  resolve  the  inflammatory  response
mediated by PAF, explaining the high rate of MOF in
these patients. These normal or decreased PAF acet-
ylhydrolase  levels  in  SS,  despite  a  great  level  of
maturation of monocytes to macrophages, might be
due to an inactivation by free oxygen radicals of the
PAF acetylhydrolase normally produced.15 In SS, these
reactive oxygen species, produced by polymorphonu-
clear cells in response to stimulation by PAF, may play
a key role in the initiation of MOF. This effect could be
mediated, in part, by this inactivation of PAF acetylhy-
drolase, leading  to  an  imbalance  between  PAF  and
PAF acetylhydrolase and to a default in the control of
the inflammatory response.
In  conclusion,  our  study  shows  that  the  macro-
phagic  differentiation  and  activation  that  occurs
during  haemophagocytosis  in  SS  patients  is  not
associated  with  increased  levels  of  PAF  acetylhy-
drolase, by contrast with a usual adequate inflamma-
tory  response. This  phenomenon  probably  reflects
the disregulated character of this response, and may
contribute to the mediation of organ dysfunctions in
this syndrome.
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